Down Rounds and Board Governance
A down round is usually described as a valuation event: the company raises at a lower price than last time, everyone takes dilution, the cap table is reset, and the business continues on worse terms than anyone hoped. Framed that way, it reads as a disappointment to be managed — bad news with paperwork attached.
That framing badly understates what is happening from a governance standpoint. The defining feature of most down rounds is not the price. It is that the money is coming from the people already sitting at the board table. The existing investors who will set the terms, approve the terms, and benefit from the terms are represented by directors who owe fiduciary duties to the company and its stockholders as a whole — including to the common holders who will be diluted, and to the smaller investors who may be washed out entirely.
That is the structural fact that makes a down round one of the most legally and ethically exposed decisions a private company board ever makes. It is also why the protections that matter have to be built into the process before terms are negotiated, not assembled afterward in response to a complaint.
(This article is governance guidance, not legal advice. Standards vary by jurisdiction and entity, and Delaware law in this area has been actively developing; any board facing a down round should be working with qualified counsel from the outset.)
Why Clinical-Stage Companies Land Here
Biopharma is structurally prone to down rounds in a way that many sectors are not. Value in a clinical-stage company moves in steps tied to data, not in a smooth curve tied to revenue. A company that raised at a valuation premised on a successful readout, and then produced an ambiguous or disappointing one, has not merely grown more slowly than planned — it has had the central assumption behind its last valuation weakened. There is often no operating performance to fall back on and no revenue line to reprice against.
Layer onto that the sector's capital intensity and the sensitivity of the biotech financing window to broader market conditions, and the result is a familiar pattern: a company that needs another two years of money, whose last round was priced in a friendlier market against a thesis that has since become harder to defend, approaching investors who now see the same asset differently.
The board's job in that moment is not to prevent the down round. Often the down round is the right answer — better than a sale from weakness, better than running out of cash. The job is to make sure it happens through a process that can withstand scrutiny and that treats the constituencies who are not in the room fairly.
The Legal Exposure, Stated Plainly
Directors ordinarily enjoy considerable deference: courts generally do not second-guess business decisions made by disinterested directors in good faith. That deference is not available when the board is conflicted or when the financing is being done at the behest of a controlling stockholder. In that situation the transaction is instead subject to Delaware's most demanding standard of review, entire fairness, under which the board bears the burden of proving that both the negotiation process and the economic terms were fair.
Two features of that make it worth a board's full attention. First, the burden is reversed: rather than a plaintiff having to show the board did something wrong, the directors have to affirmatively demonstrate fairness — a position that is expensive to defend and difficult to escape early in litigation. Second, the trigger is lower than boards assume. A conflicted board majority is enough. And "controlling stockholder" is not limited to majority holders; courts have found a fund holding a minority voting position to be controlling where its relationships with the directors gave it sufficient influence, with that conflict pulling the financing into entire fairness review.
The burden can be shifted back toward the plaintiff, and this is where governance design earns its keep. Two mechanisms do that work: approval by a well-functioning committee of genuinely independent directors, or a fully informed vote of a majority of the disinterested stockholders. Neither is a formality. A committee that exists but cannot actually say no provides very little — a recent Chancery decision involving a cram-down financing found that a committee empowered only to recommend rather than to veto offered scant protection where half the board was conflicted, including an officer-director whose continued employment depended on the transaction closing.
It is also worth boards knowing that Delaware's statutory framework governing conflicted transactions has been amended recently, creating a safe-harbor path that a conflicted-board financing can be deliberately structured to fit. That is precisely the kind of thing that has to be designed in at the beginning with counsel, not discovered later.
The Structures, and What They Do to People
A board cannot govern terms it does not understand. A few mechanics recur and deserve directors' specific attention.
Anti-dilution adjustments in existing preferred stock automatically reprice earlier investors when a lower-priced round occurs. Whether the adjustment is a broad-based weighted average or a full ratchet makes an enormous difference to how much of the dilution lands on common holders rather than on the protected preferred. The board should understand, in numbers, who actually bears the dilution under the existing documents before it evaluates any new proposal.
Pay-to-play provisions require existing investors to participate in the new round or suffer a consequence — commonly forced conversion of their preferred into common, stripping their liquidation preference and protective rights. These provisions have a legitimate purpose: they push existing holders to support the company rather than free-ride. They can also be constructed coercively. Courts have made clear that a pay-to-play structure which eliminates non-participating stockholders' contractual protections is not insulated from scrutiny merely because access was nominally equal to everyone. Where lead investors had pre-allocated the overwhelming majority of the round to themselves, gave others a narrow window to decide, and conditioned diligence access on subscribing first, the formal availability of participation did not cure the coercion.
Recapitalizations and cram-downs go further, restructuring the entire capital stack and sometimes reducing prior holders to a fraction of their former position. Here a board should understand a point that is uncomfortable but important: where the common stock genuinely has no value at the time of the transaction, it can be fair for common holders to receive nothing. That is a real principle, not a loophole. But fair price alone does not carry a transaction — process failures can sink a financing whose economics were defensible, and a board that tells itself the price justifies everything has misunderstood the standard.
Option repricing and retention follow closely behind. A down round frequently leaves employee equity underwater, and the company will need to address retention through repricing, new grants, or a refreshed pool — which is itself dilutive and which benefits management, including the executives advising the board on the financing. That overlap deserves its own conscious handling rather than being folded into the round as an afterthought.
Building a Process That Holds Up
The measures that protect a board are well established, and their common feature is that they must be in place early — before terms harden, while there is still negotiating leverage to deploy.
Identify conflicts at the outset and act on them. Every director should disclose their fund's intended participation, any side arrangements, and any interest in the outcome. The board, with counsel, then decides who is actually conflicted and how to neutralize it. Doing this at the start rather than at signing is what determines the standard of review the whole transaction is later judged against.
Form a special committee of genuinely disinterested directors, and give it real power. The committee must be able to negotiate and to reject, not merely to bless. If a majority of the board is interested, the committee is not optional. And the committee needs its own counsel — advisors whose loyalty runs to the committee rather than to the company's regular relationships with the lead investors.
Establish value independently. Research comparable transactions. Obtain a fairness opinion where the circumstances warrant it. A recurring judicial criticism in failed down-round cases is that directors could not explain where the valuation they approved actually came from. A board that adopts a number supplied by the investors funding the round, without independent work, has no answer to that question.
Offer participation broadly and genuinely. A rights offering that lets all stockholders participate on the same terms as the lead investors is one of the strongest available protections, both because it is fair and because it undercuts the claim that insiders helped themselves at others' expense. The word that matters is genuinely: same terms, adequate time, equal information, and no meaningful pre-allocation that makes the offer illusory.
Consider disinterested stockholder approval. A fully informed vote of the disinterested holders is the other route to shifting the burden. It takes time and disclosure discipline, which is precisely why boards facing a cash cliff skip it — another argument for starting the process before the cliff arrives.
Document contemporaneously. Minutes that record the alternatives considered, the conflicts identified and how they were handled, the basis for the valuation, and why the board concluded as it did are both a discipline that improves the decision and the record that will be read years later.
The Constituencies Not in the Room
Beyond the legal frame, a down round distributes pain among people with very different levels of representation, and the board is the only body responsible to all of them.
Common holders — founders and employees — typically absorb the heaviest dilution while having the least voice. Small investors without the capacity to participate in a pay-to-play may lose protections they paid for. Employees watch their equity go underwater in a company where equity was a substantial part of why they joined. None of these outcomes is necessarily wrong; sometimes they are unavoidable. But a board that has not explicitly asked who bears the cost, and whether the allocation is defensible, has not done the work.
There is a corresponding point on the other side worth noting: investors who refuse to participate and then attempt to block the financing are not automatically acting within their rights. Delaware has found that a stockholder playing hardball to obstruct a needed financing can itself breach duties. A board facing an investor holding out for better terms should know that the pressure does not run only one way.
The Traps
Waiting until the cash cliff. Nearly every protective measure above — an independent committee, independent valuation work, a rights offering, a stockholder vote — requires time. A board that begins the process with six weeks of runway has forfeited them all and will accept whatever the insiders propose. The governance failure occurred months earlier.
Treating the special committee as a formality. A committee that cannot veto, or whose members have their own stakes, creates the appearance of protection without the substance, and courts have said so.
Assuming a fair price cures the process. It does not. Both prongs have to hold.
Letting the lead investor's counsel run the process. The company's regular counsel and the lead investor's counsel are not substitutes for independent advice to a committee whose job is to negotiate against those investors.
Forgetting that fund designees expose their funds. Sponsors can face aiding-and-abetting exposure for conduct undertaken through their board designees. Investor directors sometimes assume the risk is the company's alone; it is not, and pointing that out can be a useful way to get serious process attention from the very people who most need to give it.
The Underlying Principle
A down round is a test of whether a board is genuinely a board or merely a forum where the largest investors formalize decisions they have already made. The circumstances push hard toward the latter: the company needs money, the insiders are the only ones offering it, time is short, and everyone at the table is tired of the situation.
The discipline that distinguishes the two is unglamorous and almost entirely front-loaded. Surface the conflicts before terms are discussed. Put genuinely independent directors in charge of the negotiation and give them the power to walk away. Find out what the company is actually worth from someone with no stake in the answer. Let everyone participate on the same terms, with real time and real information. Write down why.
A board that does those things can approve a painful financing and defend it — to the common holders, to the employees, to the investors who could not participate, and to a court if it comes to that. A board that skips them may reach exactly the same price and be unable to defend any of it.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.